How much would it cost to bring this repurposed drug to market?+
Carbamazepine already exists in generic form, which the project specifically highlights as making it an affordable repurposed therapy. Development costs are significantly lower than a new molecule since manufacturing, safety data, and supply chains already exist. However, the remaining costs for completing regulatory filings (Marketing Authorization Application) are not specified in the project data.
Can this scale beyond the initial rare disease indication?+
The project targets MCDS specifically (fewer than 1 in 100,000 people), but genetic skeletal diseases as a group include over 450 unique phenotypes affecting at least 1 per 4,000 children — roughly 225,000 people across the EU. If the mechanism of alleviating ER stress proves transferable to related conditions, the addressable market expands considerably. The biomarker work could help identify which patients across these conditions might respond.
What is the IP and licensing situation?+
Carbamazepine is an off-patent, generic drug, so there are no molecule patents to license. However, the orphan drug designation granted by the European Commission in September 2016 provides market exclusivity for the MCDS indication in Europe. The clinical trial data, biomarkers, and health economics models generated by this 12-partner consortium represent the proprietary value.
What regulatory approvals has this achieved so far?+
The drug received European Commission orphan drug designation for MCDS treatment in September 2016. Carbamazepine is already FDA-approved for epilepsy and bipolar disorder. The project conducted Phase 1 and Phase 2/3 multinational clinical trials across EU countries and Australia, aiming to advance up to the Marketing Authorization Application dossier.
What is the project timeline and current status?+
The project ran from December 2017 to May 2024 (extended from the original 2022 end date due to COVID-related delays). It is now closed. The clinical trials were multinational, conducted across sites in the UK, Germany, Italy, France, Belgium, and Australia.
What health economics evidence is available?+
The project developed conceptual Budget Impact Analysis and Cost-Effectiveness Analysis models mapping disease natural history and care sequences in the UK, Germany, and Italy. These models provide the economic evidence base that payers and health technology assessment bodies typically require before approving reimbursement for orphan drugs.
Who are the key partners and what expertise do they bring?+
The consortium includes 12 partners across 6 countries, with world-renowned clinical centres and SMEs. It comprises 3 universities, 6 research organisations, and 2 industry partners (including 2 SMEs). The coordinator is the University of Newcastle upon Tyne in the UK, a leading centre for skeletal disease research.
